In Conversation with Tobe Aleksander, who talks to Nona about her PV, when it was diagnosed and the treatment she has been receiving to manage it and why she decided to take part in the Mithridate Study.
This is part 1 of a series of 3 conversations that Tobe and Nona will have about Tobe’s experiences on the study – part 1 enrolling and starting the study; part 2 mid-way through the study; part 3 end of the study, overall experience and going forward. (parts 2 and 3 will be recorded and published in due course)
The Mithridate Study is an international multi-centre study, set-up to investigate which treatment is most effective for patients who have high-risk PV (polycythaemia vera). The study will test how safe and effective Ruxolitinib is compared to the current BAT (best available therapy) either Hydroxycarbamide or Interferon Alpha. The Mithridate Study is sponsored by MPN Voice; University of Birmingham; Institut National du Cancer; Novartis.
More information, including a list of hospitals running the study, can be found here. If you would like to take part in the Mithridate Study or any other study/trial, please speak to your haematologist.
We hope that you enjoyed this conversation, please send feedback and any questions to info@mpnvoice.org.uk. If you have any suggestions for future conversations please let us know.
We would like to thank Tobe for taking part in this conversation with Nona and look forward to the next instalment.
Donate to MPN Voice – MPN Voice would not exist without donations, fundraising and grants, we are kindly asking everyone to be as generous as they can to help us support our ongoing projects supporting the MPN patient and healthcare communities. We would be very grateful for your support with a donation to MPN Voice which you can make via the MPN Voice JustGiving page, thank you.
